65th ASH Annual Meeting & Exposition: ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia

ASH Poster Walks

Lymphoid Leukemias, Research, Translational Research, genomics, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Biological Processes, molecular biology, pathogenesis

(Virtual Program)

This poster walk explores the pivotal role of genetic mutations in Acute Myelogenous Leukemia (AML) and Myeloma, underscoring their significant prognostic implications. Attendees will gain insights into emerging mutations, their reporting and research methodologies, and the transformative effect they have on treatment strategies and prognosis. By delving into these timeless genetic mutations, this presentation aims to keep participants abreast of the latest developments and inspire contemplation about the future of research in this critical area of oncology. This discussion aligns with ASH's research agenda aimed at expanding the understanding and development of cytogenetics to enhance patient outcomes.

2940

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Daniel I. Nathan, MD¹, Ronald Hoffman, MD², Daiva Ahire³^*, John Mascarenhas, MD¹^*, Lewis R. Silverman, MD¹, Vesna Najfeld, PhD^1,3 and Jonathan Feld, MD¹

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
³Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

1563

T-Cells Immune Cluster Analysis Using Cytof Identifies Unique Patient Subgroups with TP53 Mutation and Predicts Complete Remission (CR) in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax Plus Hypomethylating Agent Therapy

Talha Badar, MD¹, Keith Knutson²^*, James M. Foran, MD³, Naseema Gangat, MBBS⁴, Kevin Pavelko, Ph.D.⁵^*, Scott H. Kaufmann, MD, PhD⁵, Mark R. Litzow, MD⁴, Hemant S. Murthy, MD⁶, Davitte Cogen²^*, Margaret Ushman²^*, Arini Arsana⁷^*, Aref Al-Kali, MD⁴, Hassan Alkhateeb, MD⁴^*, Ayalew Tefferi, MD⁴, Mrinal M. Patnaik, MD, MBBS⁸ and Mithun V Shah, MD, PhD⁴

¹Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL
²Mayo Clinic, Jacksonville, FL
³Hematology/Oncology, Mayo Clinic, Jacksonville, FL
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Mayo Clinic, Rochester, MN
⁶Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL
⁷Mayo Clinic, Rochester
⁸Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN

1581

Proteomic Profiling Identifies Unique IDH Mutant Signatures and Novel Therapeutic Opportunities in Adult Acute Myeloid Leukemia Patients

Eduardo Sabino de Camargo Magalhaes, MD¹^*, Stefan Hubner²^*, Brandon D. Brown, MD³^*, Yihua Qiu⁴^* and Steven M. Kornblau, MD⁴

¹Department of Ageing Biology/ERIBA, University Medical Center Groningen, Groningen, Netherlands
²John Sealy School of Medicine, The University of Texas Medical Branch (UTMB), Galveston, TX
³Department of Pediatrics, MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

4681

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Alina Dulau-Florea, MD¹^*, Raul C. Braylan, MD², Yanna Ding³^*, Nisha Patel, DO⁴, Katherine Calvo, MD, PhD⁵, Elizabeth Hill, MD³^*, Emma M. Groarke, MD^6,7, Neal S. Young, MD^7,8 and Bhavisha A. Patel, MD^7,9

¹Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD
²National Institutes of Health, Bethesda, MD
³National Cancer Institute, National Institutes of Health, Bethesda, MD
⁴Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD
⁵National Institutes of Health Clinical Center, Bethesda, MD
⁶Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD
⁷Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
⁸National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD
⁹Hematology Branch, National Heart, Lung, and Blood Institute. National Institutes of Health, Bethesda, MD

3320

Mutant N- and K-Ras Show Distinct Effects on Growth, Signaling and Drug Response in CRISPR-Cas Edited Alleles of a Myeloma Cell Line

Brian Van Ness, PhD¹, Amit K Mitra, PhD, MSc²^*, Lisa Wiesen³^*, Linda Banovic Baughn, PhD^4,5, Shaji Kunnathu Kumar, MD⁶, Joachim Petit⁷^*, Jeremiah Pfizer⁸^* and Kelli Gyotoku⁵^*

¹Department of Genetics, Cell biology & Development, University of Minnesota, Twin Cities, Minneapolis, MN
²Dept Drug Discovery and Development, Auburn University, Auburn, AL
³Cancer Center, Universiyt of Minnesota, Minneapolis, MN
⁴Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN
⁵Mayo Clinic, Rochester, MN
⁶Division of Hematology, Mayo Clinic, Rochester, MN
⁷Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
⁸Drug Discovery and Development, Auburn University, Auburn, AL

1945

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Holly Lee, MD¹^*, Sungwoo Ahn, PhD¹^*, Ranjan Maity, PhD¹^*, Noemie Leblay, PhD²^*, Michael Durante, PhD³^*, Bachisio Ziccheddu³^*, Alexis Brake³^*, Remi Tilmont, MD¹^*, Elie Barakat¹^*, Mansour Poorebrahim, PhD²^*, Ola Landgren, MD³, Benjamin Diamond, MD³, Francesco Maura, MD⁴, Paola Neri, MD, PhD² and Nizar J Bahlis, MD²

¹Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
²Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
³Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL
⁴Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, PALMETTO BAY, FL

See more of: ASH Poster Walks

<< Previous Poster Walk Application | Next Poster Walk Application >>